- The Drugs Controller General of India (DCGI) of the Central Drugs Standard Control Organization (CDSCO) has approved Phase 2 COVID-19 trial of Ampio Pharmaceuticals Inc's AMPE Ampion.
- The study will utilize inhaled Ampion to treat those suffering from respiratory distress due to COVID-19.
- Related Link: Ampio Pharma's Inhaled COVID-19 Treatment Shows 78% Improvement In All-Cause Mortality.
- The AP-019 treatment protocol was approved with no recommended changes.
- Related: Ampio's US Phase 2 Study Of Inhaled Ampion In COVID-19 Patients Gets Underway.
- Price Action: AMPE stock is up 5.34% at $1.73 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
